Clinical trial NCT01144858: Clinical Value of Left Atrial Appendage Flow for Prediction of Successful Catheter Ablation for Persistent Atrial Fibrillation
Official title: Clinical Value of Left Atrial Appendage Flow for Prediction of Successful Catheter Ablation for Persistent Atrial Fibrillation
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Persistent Atrial Fibrillation
Catheter Ablation
Keywords: atrial fibrillation
ablation catheter
left atrial appendage peak emptying velocity
tool for predicting successful catheter ablation
Lead sponsor: Clinique Pasteur
Sponsor class: OTHER
First posted: 2010-06-16
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 40 consecutive patients who underwent first-time radiofrequency catheter ablation for pAF. pAF was defined as continuous AF lasting longer than 1 month, resistant to either electrical or pharmacological cardioversion

Brief summary: The purpose of this study was to determine whether left atrial appendage flow velocity, as determined using trans esophageal echocardiography (TEE), predicts the outcome after catheter ablation of persistent Atrial fibrillation( pAF).

Detailed description: 40 PAF patients underwent 3D mapping and ablation. A stepwise approach including circumferential pulmonary vein (PV) isolation, continuous complex-fractionated electrogram (CFE) ablation and linear ablation was performed by the same operator. The procedural end point was termination of persistent AF by catheter ablation, either by conversion directly to sinus rhythm or to atrial tachycardia. Left atrial appendage (LAA) peak flow velocities were measured with transesophageal echography and averaged within each RR interval of 10 consecutive cardiac cycles.

Eligibility criteria: Inclusion Criteria:

* First-time radiofrequency catheter ablation for pAF. pAF was defined as continuous AF lasting longer than 1 month, resistant to either electrical or pharmacological cardioversion.
* Informed consent

Exclusion Criteria:

* Severe valvular disease requiring surgery
* Valvular prosthesis
* Known severe coronary artery disease
* Atrial and/or ventricular thrombosis
* New York Heart Association functional class III to IV
* Cerebrovascular disease
* Pulmonary embolism
* Latent or manifest hyperthyroidism

Primary outcomes:
measure: termination of persistent AF by catheter ablation
Secondary outcomes:
measure: Recurrences of AF were therefore determined from holter monitoring at 3 and 6 months or 12 leads ECG in care of symptomatic palpitation with clinical interview.
Other outcomes:
Locations:
city: Toulouse
country: France
facility: Clinique Pasteur
state: 43-45 avenue de Lombez
Study officials:
References:
citation: Combes S, Jacob S, Combes N, Karam N, Chaumeil A, Guy-Moyat B, Treguer F, Deplagne A, Boveda S, Marijon E, Albenque JP. Predicting favourable outcomes in the setting of radiofrequency catheter ablation of long-standing persistent atrial fibrillation: a pilot study assessing the value of left atrial appendage peak flow velocity. Arch Cardiovasc Dis. 2013 Jan;106(1):36-43. doi: 10.1016/j.acvd.2012.09.002. Epub 2012 Dec 20.